| TOP PICK | 4.170 | Serge Depatie | Treats atrial fibrillation (irregular heartbeat). This is a large coming market in cardiac area that is unsolved. The clinical trials they are doing in the US and Europe are indicating that the doctors are really adopting the product. Will probably be the leading therapy in this area. Expecting a takeout, especially if they get FDA approval. | 2008-05-07 | |
| Comment | 2.920 | Hugh Cleland, CFA | Has some experts telling him he should be looking at this again. | 2007-01-24 | |
| HOLD | 6.600 | Glenn Paradis, BA, CFA | As a medical device company its got its risks. The market they are in is not fully developed, so they need to clear the FDA hurdles, develop a market and hit their milestones. Arctic Circler(R) should be a very big piece of that. Expects to have some very good news in 05/06 on this. | 2005-01-13 | |
| DON'T BUY | 6.350 | Peter Hodson | Just did a financing and the stock can't seem to get beyond the financing price. Unfortunately had to raise cash to get to the next level. Likes the product and the management team. Longer term, it's a good keeper, but doesn't expect a whole lot in the short term. Their US revenues have to ramp up before the market gets excited. Selling his position. | 2004-12-20 | |
| HOLD | 6.400 | Robert Floyd | Recently did a financing which is typical for a lot of biotech companies. Their research is very interesting. Trying to increase their marketing internationally. | 2004-12-17 | |
| WEAK BUY | 6.750 | Glenn Paradis, BA, CFA | Using freezing instead of heat to treat injuries to the heart will be the big driver next year. Good technology that is being accepted. Long term should be good, but short term would be concerned about general market risk. | 2004-10-14 | |
| BUY | 6.660 | Peter Hodson | Well managed and well financed. Takeover is a possibility. | 2004-09-24 | |
| VAGUE | 6.710 | Werner Muehelemann | The market is looking for more sales from this company. | 2004-09-07 | |
| HOLD | 6.770 | Glenn Paradis, BA, CFA | The value for stock will increase to 8 dollars. Therefore, hold the stocks. | 2004-08-26 | |
| WAIT | 6.950 | Ed Ho | Have a great noninvasive product to deal with heart problems. Have a new products in the pipeline. Good potential, but may be fully valued. | 2004-07-30 | |
| BUY | 7.560 | Peter Hodson | Have a better product for surgeons to cure ablation of the heart. Starting to ramp up with approval in Europe and the US. Next quarter is important as you want to see the hockey stick ramp continue. | 2004-07-08 | |
| BUY | 8.320 | Robert Floyd | Likes both the product and the space. | 2004-06-28 | |
| BUY | 7.300 | Peter Hodson | Making substantial progress. The procedure they do takes less time and it had 100% success rate. Starting to see surgeons adopt this. The company will ultimately be sold. | 2004-05-17 | |
| BUY | 6.520 | Glenn Paradis, BA, CFA | In a very large and growing market. A technology that is getting more and more accepted. Expecting very large revenue growth out of them this year. New products coming out in the third quarter. Could eventually be a takeover target. | 2004-04-22 | |
| DON'T BUY | 6.440 | Andrew McCreath | Medical device companies are a bit of a minefield because big boys like Abbott, Baxter, Johnson & Johnson control the purchasing through a hospital. Interesting technology. Using a lot of cash. Wait to see their numbers. A high risk situation. | 2004-04-20 | |
| WAIT | 6.180 | Peter Hodson | Good management. Have a better surgical procedure. People are starting to be convinced that it is better. Could be approaching the hockey stick growth curve. Wait for confirmation that revenues are accelerating. | 2004-03-23 | |
| WEAK BUY | 5.840 | Peter Hodson | In a transition area. Pretty good product. Think they've turned a corner and should have a good year. | 2004-02-20 | |
| DON'T BUY | 5.590 | Robert McWhirter | Have very good technology. Earnings improved from minus .96 cents to minus.41 cents. Stock ranks in the bottom 10% of the database. | 2004-01-15 | |
| PAST TOP PICK | 4.770 | Glenn Paradis, BA, CFA | (Top pick Aug 13/03. Down 25%.) Saw a very large shareholder sell which drove down the stock price. That has to be digested. Should see revenues ramping up and new product approvals happening. Good technology. | 2003-10-24 | |
| TOP PICK | 6.390 | Glenn Paradis, BA, CFA | Focused on cardiovascular and intro fibrillation market.Should see sales ramp up this year.A very rapidly growing space.There is a potential for a take out. | 2003-08-13 | |
| DON'T BUY | 6.100 | Peter Hodson | A very good company. Starting to get massive approval. Would like to see better traction on revenues. Voatile. | 2003-07-10 | |
| BUY | 5.990 | Andrew McCreath | If you like biotechs, this could be OK. Speculative. | 2003-05-29 | |
| DON'T BUY | 3.600 | Robert Floyd | A little bit suspect on the company at this time. | 2003-03-27 | |
Experts that have talked about CryoCath Technologies
Rss Top Picks Feed
